

Ref: MHL/Sec&Legal/2025-26/87

February 04, 2026

To,
BSE Limited
Scrip Code: 542650

National Stock Exchange of India Ltd.
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is the Press Release as mentioned below:

“Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63%”

You are requested to take the above information on record.

Thanking you,
Yours faithfully,

For **Metropolis Healthcare Limited**

Kamlesh C Kulkarni
Head – Legal & Secretarial

Encl: A/a



PRESS RELEASE

Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63%*.

Mumbai, India, 4th February 2026: Ameera Shah-led [Metropolis Healthcare Limited](#) (NSE: **METROPOLIS** | BSE: 542650), India's second-largest and most trusted pathology laboratory chain, today announced its unaudited consolidated financial results for the quarter ended December 31st, 2026 (Q3FY26).



*PAT excluding Exceptional item (impact of new labour code): INR 9 crore

Key Operational Highlights – Q3FY26

- **Patient and Test Volumes grew 14% and 13% YoY**, respectively, supported by steady demand trends, deeper penetration across Tier II and Tier III markets, and a favourable mix shift toward complex and specialised testing.
- **B2C revenues grew 19% YoY and B2B revenues grew ~35% YoY**, driven by network expansion, improved service levels, and consistent execution across channels.
- **TruHealth and Specialty portfolios recorded strong growth of ~37% and ~34% YoY**, respectively.
- **Revenue per Test (RPT) and Revenue per Patient (RPP) increased 11% and 10% YoY**, respectively, supported by brand strength, improved test mix, and higher adoption of advanced diagnostics.
- **North India's revenue contribution at 17%**, while **Tier III cities registered 16% revenue growth** and contributing 24% to overall revenues.
- **Recent acquisitions integrated as planned, with stable margins at Core Diagnostics**, and continued outperformance from **Scientific Pathology (Agra)**, **Dr. Ahuja's Pathology & Imaging Center (Dehradun)**, and **Dr. R. S. Patil's Ambika Pathology Laboratory (Kolhapur)**.
- The Board approved a **3:1 bonus issue of equity shares**.

"The diagnostics sector in India is at a pivotal inflection point, driven by the growing adoption of preventive healthcare, a rising chronic disease burden, and the expansion of organised healthcare across Tier II and Tier III markets. Our Q3 performance reflects how Metropolis is capturing these opportunities through a clear strategic focus and sustained investments in specialised capabilities. As our genomics and advanced diagnostics platforms scale, we are building a science-led, resilient, and future-ready diagnostics institution that meaningfully advances clinical decision-making and delivers enduring value for patients, clinicians, and the wider healthcare ecosystem."

~ Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited.

“Our strong Q3 and year-to-date performance reflects disciplined execution across the business. Growth has been broad-based, supported by strong momentum across our key segments, higher B2B contribution, and effective network expansion. Improved margins in a typically lean quarter highlight the strength of our operating model and productivity gains. With integration synergies from recent acquisitions progressing well and healthy demand trends, we remain confident of achieving our full-year growth and profitability objectives.”

~ Surendran Chemmenkotil, Managing Director, Metropolis Healthcare Limited.

About Metropolis Healthcare Limited: Established in 1981, Metropolis Healthcare Limited is India’s second-largest diagnostic chain, led by visionary leader Ms. Ameera Shah. With over four decades of excellence, Metropolis has been a pioneer in delivering best-in-class diagnostic services to patients, healthcare providers, and corporates across India and Africa. The company’s extensive footprint spans 28 states, 7 Union Territories, and over 750+ towns in India, supported by a robust network of 219 laboratories, ~4,800 plus patient service centers, and over 10,000 touchpoints. Each year, Metropolis serves millions of individuals by providing actionable health insights that empower better clinical outcomes.

Metropolis offers a comprehensive range of more than 4,100 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. The company’s commitment to quality and accuracy is reinforced by its consistent CAP proficiency score of over 99% for the past decade, placing it among the top 1% of laboratories worldwide for quality assurance. The Metropolis philosophy is built on the pillars of technological superiority, a warm, patient-centric approach, and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#)

Safe harbor statement: Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company: Metropolis Healthcare Ltd. CIN -L73100MH2000PLC192798 Mr. Jeyasingh Balakrishnan Head - Corporate Communications jeyasingh.b@metropolisindia.com	Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285 Mr. Shogun Jain / Mr. Sagar Shroff +91 77383 77756 / +91 98205 19303 shogun.jain@sgapl.net / sagar.shroff@sgapl.net
---	---